Phaseline

Companies › ModeX Therapeutics, An OPKO Health Company

ModeX Therapeutics, An OPKO Health Company: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Infectious disease; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MDX2301
Monoclonal antibody against SARS-CoV-2 spike protein
–Phase 1COVID -19Sep 2027
MDX2003–Phase 1LymphomaJan 2028
MDX2001–Phase 1Biliary Tract CancerAug 2028
MDX2004–Phase 1Advanced TumorsJun 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07445971MDX2301Phase 1COVID -19Infectious diseaseSep 2027
NCT07249905MDX2003Phase 1LymphomaOncologyJan 2028
NCT06239194MDX2001Phase 1Biliary Tract CancerOncologyAug 2028
NCT07110584MDX2004Phase 1Advanced TumorsOncologyJun 2031

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.